NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,697 | +3.5% | 2,850 | 0.0% | 0.00% | – |
Q2 2023 | $1,639 | -18.2% | 2,850 | 0.0% | 0.00% | – |
Q1 2023 | $2,003 | -68.9% | 2,850 | 0.0% | 0.00% | – |
Q4 2022 | $6,441 | -28.4% | 2,850 | 0.0% | 0.00% | – |
Q3 2022 | $9,000 | -18.2% | 2,850 | 0.0% | 0.00% | – |
Q2 2022 | $11,000 | -26.7% | 2,850 | 0.0% | 0.00% | – |
Q1 2022 | $15,000 | -61.5% | 2,850 | 0.0% | 0.00% | – |
Q4 2021 | $39,000 | -23.5% | 2,850 | 0.0% | 0.00% | – |
Q3 2021 | $51,000 | +4.1% | 2,850 | 0.0% | 0.00% | – |
Q2 2021 | $49,000 | -14.0% | 2,850 | 0.0% | 0.00% | – |
Q1 2021 | $57,000 | +18.8% | 2,850 | 0.0% | 0.00% | – |
Q4 2020 | $48,000 | +2.1% | 2,850 | 0.0% | 0.00% | – |
Q3 2020 | $47,000 | -28.8% | 2,850 | 0.0% | 0.00% | – |
Q2 2020 | $66,000 | +29.4% | 2,850 | 0.0% | 0.00% | – |
Q1 2020 | $51,000 | -17.7% | 2,850 | 0.0% | 0.00% | – |
Q4 2019 | $62,000 | +17.0% | 2,850 | -1.2% | 0.00% | – |
Q3 2019 | $53,000 | -47.5% | 2,885 | +1.2% | 0.00% | -100.0% |
Q2 2019 | $101,000 | – | 2,850 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |